110 related articles for article (PubMed ID: 22803400)
21. Improved method for expression and isolation of the Mycoplasma hominis arginine deiminase from the recombinant strain of Escherichia coli.
Fayura LR; Boretsky YR; Pynyaha YV; Wheatley DN; Sibirny AA
J Biotechnol; 2013 Sep; 167(4):420-6. PubMed ID: 23928331
[TBL] [Abstract][Full Text] [Related]
22. Arginine Deiminase Enzyme Evolving as a Potential Antitumor Agent.
Somani RR; Chaskar PK
Mini Rev Med Chem; 2018; 18(4):363-368. PubMed ID: 27538511
[TBL] [Abstract][Full Text] [Related]
23. Recombinant arginine deiminase as a potential anti-angiogenic agent.
Beloussow K; Wang L; Wu J; Ann D; Shen WC
Cancer Lett; 2002 Sep; 183(2):155-62. PubMed ID: 12065090
[TBL] [Abstract][Full Text] [Related]
24. Enzymatic production of l-citrulline by hydrolysis of the guanidinium group of l-arginine with recombinant arginine deiminase.
Song W; Sun X; Chen X; Liu D; Liu L
J Biotechnol; 2015 Aug; 208():37-43. PubMed ID: 26022421
[TBL] [Abstract][Full Text] [Related]
25. Extracellular expression of natural cytosolic arginine deiminase from Pseudomonas putida and its application in the production of L-citrulline.
Su L; Ma Y; Wu J
Bioresour Technol; 2015 Nov; 196():176-83. PubMed ID: 26233330
[TBL] [Abstract][Full Text] [Related]
26. Arginine deiminase expressed in vivo, driven by human telomerase reverse transcriptase promoter, displays high hepatoma targeting and oncolytic efficiency.
Jiang H; Guo S; Xiao D; Bian X; Wang J; Wang Y; Zhou H; Cai J; Zheng Z
Oncotarget; 2017 Jun; 8(23):37694-37704. PubMed ID: 28455966
[TBL] [Abstract][Full Text] [Related]
27. Arginine deiminase: recent advances in discovery, crystal structure, and protein engineering for improved properties as an anti-tumor drug.
Han RZ; Xu GC; Dong JJ; Ni Y
Appl Microbiol Biotechnol; 2016 Jun; 100(11):4747-60. PubMed ID: 27087524
[TBL] [Abstract][Full Text] [Related]
28. The electrostatic driving force for nucleophilic catalysis in L-arginine deiminase: a combined experimental and theoretical study.
Li L; Li Z; Wang C; Xu D; Mariano PS; Guo H; Dunaway-Mariano D
Biochemistry; 2008 Apr; 47(16):4721-32. PubMed ID: 18366187
[TBL] [Abstract][Full Text] [Related]
29. Intracellular expression of arginine deiminase activates the mitochondrial apoptosis pathway by inhibiting cytosolic ferritin and inducing chromatin autophagy.
Feng Q; Bian X; Liu X; Wang Y; Zhou H; Ma X; Quan C; Yao Y; Zheng Z
BMC Cancer; 2020 Jul; 20(1):665. PubMed ID: 32677906
[TBL] [Abstract][Full Text] [Related]
30. Poly(ethylene glycol) (PEG) conjugated arginine deiminase: effects of PEG formulations on its pharmacological properties.
Holtsberg FW; Ensor CM; Steiner MR; Bomalaski JS; Clark MA
J Control Release; 2002 Apr; 80(1-3):259-71. PubMed ID: 11943403
[TBL] [Abstract][Full Text] [Related]
31. Purification, immobilization, and biochemical characterization of l-arginine deiminase from thermophilic Aspergillus fumigatus KJ434941: anticancer activity in vitro.
El-Sayed AS; Hassan MN; Nada HM
Biotechnol Prog; 2015; 31(2):396-405. PubMed ID: 25582958
[TBL] [Abstract][Full Text] [Related]
32. PEGylation and pharmacological characterization of a potential anti-tumor drug, an engineered arginine deiminase originated from Pseudomonas plecoglossicida.
Zhang L; Liu M; Jamil S; Han R; Xu G; Ni Y
Cancer Lett; 2015 Feb; 357(1):346-354. PubMed ID: 25462857
[TBL] [Abstract][Full Text] [Related]
33. Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo.
Ensor CM; Holtsberg FW; Bomalaski JS; Clark MA
Cancer Res; 2002 Oct; 62(19):5443-50. PubMed ID: 12359751
[TBL] [Abstract][Full Text] [Related]
34. Characterization of a recombinant arginine deiminase from Halothermothrix orenii and its application in citrulline production.
Wang W; Li M; Miao M; Zhang T
Biotechnol Appl Biochem; 2023 Apr; 70(2):526-536. PubMed ID: 35761421
[TBL] [Abstract][Full Text] [Related]
35. Engineering an arginine catabolizing bioconjugate: Biochemical and pharmacological characterization of PEGylated derivatives of arginine deiminase from Mycoplasma arthritidis.
Wang M; Basu A; Palm T; Hua J; Youngster S; Hwang L; Liu HC; Li X; Peng P; Zhang Y; Zhao H; Zhang Z; Longley C; Mehlig M; Borowski V; Sai P; Viswanathan M; Jang E; Petti G; Liu S; Yang K; Filpula D
Bioconjug Chem; 2006; 17(6):1447-59. PubMed ID: 17105223
[TBL] [Abstract][Full Text] [Related]
36. Arginine-Depleting Enzymes - An Increasingly Recognized Treatment Strategy for Therapy-Refractory Malignancies.
Riess C; Shokraie F; Classen CF; Kreikemeyer B; Fiedler T; Junghanss C; Maletzki C
Cell Physiol Biochem; 2018; 51(2):854-870. PubMed ID: 30466103
[TBL] [Abstract][Full Text] [Related]
37. Arginine deiminase modulates endothelial tip cells via excessive synthesis of reactive oxygen species.
Zhuo W; Song X; Zhou H; Luo Y
Biochem Soc Trans; 2011 Oct; 39(5):1376-81, suppl 2 p following 1382. PubMed ID: 21936818
[TBL] [Abstract][Full Text] [Related]
38. Biochemical characterization of the arginine degrading enzymes arginase and arginine deiminase and their effect on nitric oxide production.
Dillon BJ; Holtsberg FW; Ensor CM; Bomalaski JS; Clark MA
Med Sci Monit; 2002 Jul; 8(7):BR248-53. PubMed ID: 12118186
[TBL] [Abstract][Full Text] [Related]
39. Selective Intracellular Delivery of Recombinant Arginine Deiminase (ADI) Using pH-Sensitive Cell Penetrating Peptides To Overcome ADI Resistance in Hypoxic Breast Cancer Cells.
Yeh TH; Chen YR; Chen SY; Shen WC; Ann DK; Zaro JL; Shen LJ
Mol Pharm; 2016 Jan; 13(1):262-71. PubMed ID: 26642391
[TBL] [Abstract][Full Text] [Related]
40. Medium Optimization for Recombinant Soluble Arginine Deiminase Expression in Escherichia coli Using Response Surface Methodology.
Zarei M; Nezafat N; Morowvat MH; Dehshahri A; Ghoshoon MB; Berenjian A; Ghasemi Y
Curr Pharm Biotechnol; 2017; 18(11):935-941. PubMed ID: 29336257
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
